Cardiovascular risk prediction is improved by adding asymptomatic coronary status to routine risk assessment in type 2 diabetic patients

Diabetes Care

Volumn 34, Issue 9, 2011, Pages 2101-2107

  Cosson, Emmanuel ^a   Nguyen, Minh Tuan ^a   Chanu, Bernard ^a   Banu, Isabela ^a   Chiheb, Sabrina ^a   Balta, Cristina ^a   Takbou, Karim ^a   Valensi, Paul ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ASYMPTOMATIC DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL PERFUSION IMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTION; PROSPECTIVE STUDY; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; SILENT MYOCARDIAL ISCHEMIA; TRANSLUMINAL CORONARY ANGIOPLASTY; CARDIOVASCULAR DISEASE; HEART MUSCLE ISCHEMIA; METHODOLOGY; MIDDLE AGED;

AGED; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK ASSESSMENT;

EID: 83455265866     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0480     Document Type: Article

References (25)

1. Puel J, Valensi P, Vanzetto G, et al.; ALFEDIAM; SFC. Identification of myocardial ischemia in the diabetic patient. Joint ALFEDIAM and SFC recommendations. Diabetes Metab 2004;30:3S3-3S18
2. Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ; ADA. Screening for coronary artery disease in patients with diabetes. Diabetes Care 2007;30:2729-2736 (Pubitemid 47547828)
3. Stevens RJ, Kothari V, Adler AI, Stratton IM; United KingdomProspective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-679 (Pubitemid 33135349)
4. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847 (Pubitemid 28213628)
5. Kengne AP, Patel A, Colagiuri S, et al.; ADVANCE Collaborative Group. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia 2010;53:821-831
6. van Dieren S, Peelen LM, Nothlings U, et al. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes. Diabetologia 2011;54:264-270
7. Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for theManagement of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187 (Pubitemid 46924065)
8. Delles C, Jardine AG. Renal function and cardiovascular events: relevance of eGFR and albuminuria in patients with diabetes. Diabetologia 2011;54:4-6
9. Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care 2007;30:1742-1746 (Pubitemid 47036346)
10. Cosson E, GuimfackM, Paries J, Paycha F, Attali JR, Valensi P. Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events? Diabetes Metab 2003;29:470-476 (Pubitemid 37474258)
11. Valensi P, Pariès J, Brulport-Cerisier V, et al. Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study. Diabetes Care 2005;28:2722-2727 (Pubitemid 43951166)
12. Young LH, Wackers FJ, Chyun DA, et al.; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009;301:1547-1555
13. Cosson E, GuimfackM, Paries J, Paycha F, Attali JR, Valensi P. Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia. Diabetes Care 2003;26:1313-1314 (Pubitemid 36929292)
14. Cosson E, Nguyen MT, Pham I, Pontet M, Nitenberg A, Valensi P. N-terminal pro-Btype natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients. Diabet Med 2009;26:872-879
15. Strategies for care of the type 2 diabetic patient excluding care of complications. Recommendations of ANAES (National Agency for Health Accreditation and Evaluation) March 2000. Diabetes Metab 2000; 26(Suppl. 5):10-96 [in French]
16. Haffner SM, Lehto S, Rönnemaa T, PyöräläK, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234 (Pubitemid 28350165)
17. Sehestedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010;31:883-891
18. Nitenberg A, Pham I, Antony I, Valensi P, Attali JR, Chemla D. Cardiovascular outcome of patients with abnormal coronary vasomotion and normal coronary arteriography is worse in type 2 diabetesmellitus than in arterial hypertension: a 10 year follow-up study. Atherosclerosis 2005;183:113-120 (Pubitemid 41416829)
19. Hendel RC, Berman DS, Di Carli MF, et al.; American College of Cardiology Foundation Appropriate Use Criteria Task Force; American Society of Nuclear Cardiology; American College of Radiology; American Heart Association; American Society of Echocardiology; Society of Cardiovascular Computed Tomography; Society for Cardiovascular Magnetic Resonance; Society of Nuclear Medicine. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging: A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. J Am Coll Cardiol 2009;53:2201-2229
20. Beller GA. Noninvasive screening for coronary atherosclerosis and silent ischemia in asymptomatic type 2 diabetic patients: is it appropriate and cost-effective? J Am Coll Cardiol 2007;49: 1918-1923 (Pubitemid 46694282)
21. Miller TD, Redberg RF, Wackers FJ. Screening asymptomatic diabetic patients for coronary artery disease: why not? J Am Coll Cardiol 2006;48:761-764 (Pubitemid 44175712)
22. Bansal S, Wackers FJ, Inzucchi SE, et al.; DIAD Study Investigators. Five-year outcomes in "high-risk" participants in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study: a post-hoc analysis. Diabetes Care 2011;34:204-209
23. Valensi P, Cosson E. It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia. Diabetes Metab 2010;36:91-96
24. Faglia E, Manuela M, Antonella Q, et al. Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. Am Heart J 2005;149:e1-e6
25. Turrini F, Messora R, Giovanardi P, et al. Screening asymptomatic patients with diabetes for unknown coronary artery disease: does it reduce risk? An open-label randomized trial comparing a strategy based on exercise testing aimed at revascularization with management based on pharmacological/behavioural treatment of traditional risk factors. DADDY-D Trial (Does coronary Atherosclerosis Deserve to be Diagnosed and treated early in Diabetics?). Trials 2009;10:119